Cargando…

Differences in oxylipin profile in psoriasis versus psoriatic arthritis

BACKGROUND: Oxylipins are biological lipids that have been implicated in inflammation. We previously found that certain oxylipins correlated with clinical manifestations in psoriatic arthritis (PsA) patients. Here, we compare oxylipin profiles in PsA patients and those with psoriasis (PsO) without i...

Descripción completa

Detalles Bibliográficos
Autores principales: Coras, Roxana, Kavanaugh, Arthur, Kluzniak, Angela, Holt, Dustina, Weilgosz, Amy, Aaron, Armando, Quehenberger, Oswald, Ritchlin, Christopher, Guma, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310583/
https://www.ncbi.nlm.nih.gov/pubmed/34303373
http://dx.doi.org/10.1186/s13075-021-02575-y
_version_ 1783728790103392256
author Coras, Roxana
Kavanaugh, Arthur
Kluzniak, Angela
Holt, Dustina
Weilgosz, Amy
Aaron, Armando
Quehenberger, Oswald
Ritchlin, Christopher
Guma, Monica
author_facet Coras, Roxana
Kavanaugh, Arthur
Kluzniak, Angela
Holt, Dustina
Weilgosz, Amy
Aaron, Armando
Quehenberger, Oswald
Ritchlin, Christopher
Guma, Monica
author_sort Coras, Roxana
collection PubMed
description BACKGROUND: Oxylipins are biological lipids that have been implicated in inflammation. We previously found that certain oxylipins correlated with clinical manifestations in psoriatic arthritis (PsA) patients. Here, we compare oxylipin profiles in PsA patients and those with psoriasis (PsO) without inflammatory arthritis to identify oxylipins that associate with specific disease manifestations to better understand disease pathogenesis and identify new biomarkers. METHODS: Consecutive patients with PsA (who met the CASPAR classification criteria for PsA) and PsO were recruited from the Rheumatology Outpatient Clinic. A thorough clinical examination was performed, including entheseal (Leeds enthesitis index (LEI)) and joint involvement (SJC/TJC 66/68). Patients were evaluated for pain and global disease activity on a visual analog scale (VAS) ranging from 0 to 100. This was followed by disease activity scores calculation: cDAPSA (Disease Activity Index for Psoriatic Arthritis) and Psoriasis Area and Severity Index (PASI). Serum oxylipins were determined by mass spectrometry and their association with clinical characteristics (PASI/LEI and cDAPSA) was analyzed using Metaboanalyst 4.0 and R version 3.6.1. RESULTS: Twenty PsO (average age 52 [10.8], 55% males) and 19 PsA patients (average age 60.5 [11.4], 63.1% males) were included. PsO patients had an average body mass index (BMI) of 33.7 (6.84) and an average PASI of 3.8 (4.2). PsA patients had an average BMI of 31.9 (5.6), TJC of 9.3 (10.41), SJC of 3.7 (4.23), with an average cDAPSA of 23.3 (11.4). 63.1% of PsA patients had enthesitis (average LEI 2.2 [3]) and the same percentage had psoriasis (average PASI 3(5]). Sera were analyzed for oxylipin levels. PsO and PsA patients with higher PASI score (> 2.5) had significantly lower serum concentrations of pro-inflammatory oxylipins, most of them arachidonic acid derived (AA). Oxylipin profiling did not associate with cDAPSA. Interestingly, several AA-derived oxylipins (5,15 di-HETE (5S,15S-dihydroxy-6E,8Z,10Z,13E-eicosatetraenoic acid), 5-oxoETE (5-Oxo-eicosatetraenoic acid), PGE2 (prostaglandin E2), 11bPGE2 (11 beta prostaglandin D2), and LTB4 (leukotriene B4)) were significantly increased in PsA patients with enthesitis compared to those without. CONCLUSIONS: The AA-derived proinflammatory oxylipins were lower in both PsO and PsA patients with higher skin scores. Joint disease activity was not associated with the concentrations of oxylipins. Yet, enthesitis was associated with an increase of AA-derived pro-inflammatory oxylipins in PsA patients. Further studies are needed to determine whether oxylipin profiling can be a good biomarker of enthesitis in PsA patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02575-y.
format Online
Article
Text
id pubmed-8310583
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83105832021-07-28 Differences in oxylipin profile in psoriasis versus psoriatic arthritis Coras, Roxana Kavanaugh, Arthur Kluzniak, Angela Holt, Dustina Weilgosz, Amy Aaron, Armando Quehenberger, Oswald Ritchlin, Christopher Guma, Monica Arthritis Res Ther Research Article BACKGROUND: Oxylipins are biological lipids that have been implicated in inflammation. We previously found that certain oxylipins correlated with clinical manifestations in psoriatic arthritis (PsA) patients. Here, we compare oxylipin profiles in PsA patients and those with psoriasis (PsO) without inflammatory arthritis to identify oxylipins that associate with specific disease manifestations to better understand disease pathogenesis and identify new biomarkers. METHODS: Consecutive patients with PsA (who met the CASPAR classification criteria for PsA) and PsO were recruited from the Rheumatology Outpatient Clinic. A thorough clinical examination was performed, including entheseal (Leeds enthesitis index (LEI)) and joint involvement (SJC/TJC 66/68). Patients were evaluated for pain and global disease activity on a visual analog scale (VAS) ranging from 0 to 100. This was followed by disease activity scores calculation: cDAPSA (Disease Activity Index for Psoriatic Arthritis) and Psoriasis Area and Severity Index (PASI). Serum oxylipins were determined by mass spectrometry and their association with clinical characteristics (PASI/LEI and cDAPSA) was analyzed using Metaboanalyst 4.0 and R version 3.6.1. RESULTS: Twenty PsO (average age 52 [10.8], 55% males) and 19 PsA patients (average age 60.5 [11.4], 63.1% males) were included. PsO patients had an average body mass index (BMI) of 33.7 (6.84) and an average PASI of 3.8 (4.2). PsA patients had an average BMI of 31.9 (5.6), TJC of 9.3 (10.41), SJC of 3.7 (4.23), with an average cDAPSA of 23.3 (11.4). 63.1% of PsA patients had enthesitis (average LEI 2.2 [3]) and the same percentage had psoriasis (average PASI 3(5]). Sera were analyzed for oxylipin levels. PsO and PsA patients with higher PASI score (> 2.5) had significantly lower serum concentrations of pro-inflammatory oxylipins, most of them arachidonic acid derived (AA). Oxylipin profiling did not associate with cDAPSA. Interestingly, several AA-derived oxylipins (5,15 di-HETE (5S,15S-dihydroxy-6E,8Z,10Z,13E-eicosatetraenoic acid), 5-oxoETE (5-Oxo-eicosatetraenoic acid), PGE2 (prostaglandin E2), 11bPGE2 (11 beta prostaglandin D2), and LTB4 (leukotriene B4)) were significantly increased in PsA patients with enthesitis compared to those without. CONCLUSIONS: The AA-derived proinflammatory oxylipins were lower in both PsO and PsA patients with higher skin scores. Joint disease activity was not associated with the concentrations of oxylipins. Yet, enthesitis was associated with an increase of AA-derived pro-inflammatory oxylipins in PsA patients. Further studies are needed to determine whether oxylipin profiling can be a good biomarker of enthesitis in PsA patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02575-y. BioMed Central 2021-07-24 2021 /pmc/articles/PMC8310583/ /pubmed/34303373 http://dx.doi.org/10.1186/s13075-021-02575-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Coras, Roxana
Kavanaugh, Arthur
Kluzniak, Angela
Holt, Dustina
Weilgosz, Amy
Aaron, Armando
Quehenberger, Oswald
Ritchlin, Christopher
Guma, Monica
Differences in oxylipin profile in psoriasis versus psoriatic arthritis
title Differences in oxylipin profile in psoriasis versus psoriatic arthritis
title_full Differences in oxylipin profile in psoriasis versus psoriatic arthritis
title_fullStr Differences in oxylipin profile in psoriasis versus psoriatic arthritis
title_full_unstemmed Differences in oxylipin profile in psoriasis versus psoriatic arthritis
title_short Differences in oxylipin profile in psoriasis versus psoriatic arthritis
title_sort differences in oxylipin profile in psoriasis versus psoriatic arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310583/
https://www.ncbi.nlm.nih.gov/pubmed/34303373
http://dx.doi.org/10.1186/s13075-021-02575-y
work_keys_str_mv AT corasroxana differencesinoxylipinprofileinpsoriasisversuspsoriaticarthritis
AT kavanaugharthur differencesinoxylipinprofileinpsoriasisversuspsoriaticarthritis
AT kluzniakangela differencesinoxylipinprofileinpsoriasisversuspsoriaticarthritis
AT holtdustina differencesinoxylipinprofileinpsoriasisversuspsoriaticarthritis
AT weilgoszamy differencesinoxylipinprofileinpsoriasisversuspsoriaticarthritis
AT aaronarmando differencesinoxylipinprofileinpsoriasisversuspsoriaticarthritis
AT quehenbergeroswald differencesinoxylipinprofileinpsoriasisversuspsoriaticarthritis
AT ritchlinchristopher differencesinoxylipinprofileinpsoriasisversuspsoriaticarthritis
AT gumamonica differencesinoxylipinprofileinpsoriasisversuspsoriaticarthritis